Who is sponsoring NCT04644198?

NCT04644198 is sponsored by The University of The West Indies.

What drugs are being tested in NCT04644198?

Interventions in NCT04644198: Convalescent Plasma Infusion.

What condition does NCT04644198 study?

NCT04644198 studies COVID-19, Convalescent Plasma Treatment.

Is NCT04644198 still recruiting?

NCT04644198 is currently status unknown. Last updated 12 May 2021.

Last reviewed 2021-05-12 · How we verify

NCT04644198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica

Status unknown Phase 2 Last updated 12 May 2021

What this trial tests

Phase 2 trial testing Convalescent Plasma Infusion in COVID-19, Convalescent Plasma Treatment in 30 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
1 December 2021

1 December 2021

Quick facts

Lead sponsor	The University of The West Indies
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2021
Primary completion	1 December 2021
Estimated completion	1 December 2021
Sites	1 location across Jamaica

Drugs / interventions tested

Convalescent Plasma Infusion — full drug profile →

Conditions studied

COVID-19, Convalescent Plasma Treatment — all drugs for COVID-19, Convalescent Plasma Treatment →

Sponsor

The University of The West Indies

Who can join

Adults 18 to 65, any sex, with COVID-19, Convalescent Plasma Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection. The investigators propose to test whether the use of Convalescent plasma given to patients with severe COVID-19 disease will decrease risk of death, decrease use of ventilatory support decrease biomarkers of inflammation and improve measures of viral replication compared with controls subjects who were not transfused.Convalescent plasma, will be collected from persons who are more than 21 days post negative viral testing or 28 days post resolution of symptoms.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).
Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. · · 2022 · cited 33× · PMID 35074571 · DOI 10.1016/j.intimp.2022.108536
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Chavda VP, Bezbaruah R, Dolia S, Shah N, et al · · 2023 · cited 10× · PMID 36741339 · DOI 10.1016/j.procbio.2023.01.018
The immunology and immunotherapy for COVID-19.
Liu Y, Zhou X, Liu X, Jiang X. · · 2021 · cited 3× · PMID 34915958 · DOI 10.1017/erm.2021.30

Verify or expand the search:

Other The University of The West Indies trials

Trials by the same sponsor.

NCT07177001 — Neck and Low Back Pain in Physical Therapy Students at The University of the West Indies, Mona, Jamaica · NA · not yet recruiting
NCT07167888 — Low Back and Neck Pain in Nursing Students at The University of The West Indies · NA · not yet recruiting
NCT07194746 — The Prevalence of Neck and Low Back Pain in FMSTRC Staff At the UWI Mona · NA · not yet recruiting
NCT05856968 — Investigation of Continuous Versus Interrupted Subcutaneous Fat Closure in Reducing Surgical Site Infection · NA · not yet recruiting
NCT05730244 — A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04644198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of The West Indies
Last refreshed: 12 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04644198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing